GZMK and prostate adenocarcinoma: Mice grafted with prostate adenocarcinoma cells treated with MCTP-39, an inhibitor of the HMT WHSC1, showed increased NK cell effector function, CD107a, Granzyme-K (GZMK) and IFN-γ expression (158).